Scientific Programme

Programme-at-a-Glance

     

THURSDAY 7 JUNE

FRIDAY 8 JUNE

SATURDAY 9 JUNE

09:30 - 12:30
Ultrasound / Fibro scan Workshop 1
Room 332, Level 3

07:30 - 08:30
Preceptorship Programme -
Early Morning Workshop 1

07:30 - 08:30
Preceptorship Programme -
Early Morning Workshop 3

12:00 - 18:30
Hepatitis Elimination Symposium
Room 331, Level 3

07:30 - 08:30
Preceptorship Programme -
Early Morning Workshop 2

07:30 - 08:30
Preceptorship Programme -
Early Morning Workshop 4

13:00 - 18:00
Preceptorship Programme
Summit 2, Level 3

08:30 - 18:00
SHC 2018
Summit 2, Level 3

08:30 - 18:00
SHC 2018
Summit 2, Level 3

14:00 - 17:30
Ultrasound / Fibro scan Workshop 2
Room 332, Level 3

10:00 - 18:00
Science of HBV Cure
Room 331, Level 3

09:00 - 18:00
Science of HBV Cure
Room 331, Level 3

* All information is correct at time of update and is subject to changes. Updated as of 31 May 2018 

Science of HBV Cure 2018 Programme

FRIDAY 8 JUNE 2018 – ROOM 331

Time

Programme

10:00 - 11:05

HBV Cure Overview

Chair and Moderator : Seng Gee Lim (Singapore)

10:00 – 10:10

Opening lecture: WHO HBV Elimination Targets and Strategy

Philippa Easterbrook, WHO, Switzerland

10:10 – 10:20

International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) update 2018           

Peter Revill, Victorian Infectious Diseases Reference Laboratory, Australia

10:20 – 10:40

HBV Forum: update 2018

Veronica Miller, The UC Berkeley School of Public Health, USA

10:40 – 10:55

Insights for HBV cure from HIV cure strategies

Sharon Lewin, The Peter Doherty Institute for Infection and Immunity, Australia

10:55 – 11:05

Discussion forum led by the Moderator

11:05 – 11:50

Models for HBV Infection

Chair and Moderator : Atefeh Khakpoor (Singapore)

11:05 – 11:20

HBV cell culture models: advantages and limitations

Stephan Urban, Heidelberg University Hospital, Germany

11:20 – 11:35

What can we learn from animal models of CHB?

Qingfeng Chen, Institute of Molecular and Cell Biology (IMCB), Singapore

11:35 – 11:50

Discussion forum led by the Moderator

11:50 – 13:00

Lunch

13:00 – 14:15

Clinical & Translational Forum

Chair and Moderator: Peter Revill (Australia)

13:00 – 13:15

Viral evolution and immune interaction in HBV 

Martin Hibberd, Genome Institute of Singapore

Invited Oral & Free Paper Presentations

13:15 – 13:30

Development of novel markers of treatment response

Gavin Cloherty, Abbott Diagnostics

13:30 – 13:45

HBV RNA Splice variants in virus infection

Pei-Jer Chen, National Taiwan University Hospital

13:45 – 14:00

Viral evolution leads to replicatively efficient mutations in HBV flares

Chong Hui Heng, National University of Singapore

14:00 – 14:15

Discussion forum led by the Moderator

14:30 – 15:25

Viral Transcription

Chair and Moderator: Stephen Locarnini (Australia)

14:15 – 14:30

Targeting HBV transcription

Massimo Levrero, Sapienza University in Rome, Italy

Invited Oral & Free Paper Presentations

14:30 – 14:45

What can we learn from interferon in HBV cure?

Zhenghong Yuan, Fudan University, China

14:45 – 14:55

Epidrug screening, HITs identification and functional validation of drug targets against Hepatitis B Virus

BC Narmada, Genome Institute of Singapore, A*STAR

14:55 – 15:05

HBV large surface antigen induces Plk1-dependent checkpoint attenuation and hence hepatocyte hyperploidy

Tian-Neng Li, National Tsing Hua University, Taiwan

15:05 – 15:10

Durable inhibition of HBV replication and antigenemia by subcutaneously administered siRNA agent AB-729 in preclinical models

Amy Lee, Arbutus Biopharma

15:10 – 15:25

Discussion forum led by the Moderator

15:25 – 15:40

Tea Break

15:40 – 17:20

Capsid Inhibition

Chair and Moderator: Robert Gish (USA)

15:40 – 15:55

Mechanism and efficacy of capsid inhibitors

Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia

Invited Oral & Free Paper Presentations

15:55 – 16:05

JNJ-6379; a novel capsid assembly modulator demonstrates potent antiviral activity and a good safety profile in patients with HBeAg-positive and negative chronic hepatitis B

Oliver Lenz, Janssen Pharmaceutica 

16:05 – 16:15

RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated

Edward Gane, University of Auckland, New Zealand

16:15 – 16:25

Capsid inhibitor AB-506 complements anti-HBV activities of NUCs and investigational antigen inhibitors in preclinical combination studies

Amy Lee, Arbutus Biopharma

16:25 – 16:35

Extracellular HBV RNAs mainly consists of RNA intermediates generated in viral DNA replication process within virions and capsid-derived particles

Xiaonan Zhang, Fudan University, China

16:35 – 16:45

Targeting HBV Core Protein to Increase Cure

Uri Lopatin, Assembly

16:45 – 17:00

Discussion forum led by the Moderator

17:00 – 17:30

Special Lecture

Chair and Moderator: Man-Fung Yuen (Hong Kong)

17:00 – 17:15

Can blocking viral entry lead to HBV functional cure?

Stephan Urban, Heidelberg University Hospital, Germany

17:15 – 17:30

Discussion forum led by the Moderator

17:30 – 18:20

Reducing Viral Antigens

Chair and Moderator: Massimo Levrero (Italy)

17:30 – 17:45

Can reduction in viral antigens lead to immune reconstitution?

Robert Thimme, University Hospital of Freiburg, Germany

Invited Oral & Free Paper Presentations

17:45 – 17:55

Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB

Bruce Given, Arrowhead Pharmaceuticals

17:55 – 18:05

Clearing serum HBsAg with nucleic acid polymers – mechanistic insights and clinical impact

Andrew Vaillant, Replicor

18:05 – 18:20

Discussion forum led by the Moderator

End of Day 1

 

 

 

SATURDAY 9 JUNE 2018 – ROOM 331

09:00 – 09:50

Debate: Can HBV be cured by antiviral therapy alone?

Chair and Moderator: Edward Gane (New Zealand)

09:00 – 09:30

Yes:     Stephen Locarnini (Australia)

No:      Antonio Bertoletti (Singapore) 

09:30 – 09:50

Discussion forum led by the Moderator

09:50 – 11:20

Immunology Forum Part 1

Chair and Moderator: Sharon Lewin (Australia)

09:50 – 10:05

Characteristics of immune clearance of HBV in Chronic Hepatitis B

Robert Thimme, University Hospital of Freiburg, Germany

Invited Oral & Free Paper Presentations

10:05 – 10:20

Evidence of innate immunity in viral clearance in CHB

John Connolly, Institute of Molecular and Cell Biology (IMCB), Singapore

10:20 – 10:30

GS-9688: an oral TLR8 agonist

Anuj Gaggar, Gilead Sciences

10:30 – 10:40

Inarigivir; a potent oral selective immune-modulator for HBV cure

Nezam Afdhal, Spring Bank Pharmaceuticals

10:40 – 10:50

RO7020531, a novel prodrug of a toll-like receptor 7 agonist, is safe, well tolerated and activates TLR signaling in healthy volunteers

Ilia Folitar, Roche

10:50 – 11:20

Discussion forum led by the Moderator

11:20 -11:40

Tea Break

11:40 – 13:15

Immunology Forum Part 2

Chair and Moderator: Alex Thompson (Australia)

11:40 – 11:55

T-cell receptor therapy for clearance of HBV

Antonio Bertoletti, Duke-NUS Graduate Medical School, Singapore

Invited Oral & Free Paper Presentations

11:55 – 12:10

T-cell phenotyping in CHB and viral clearance

Yang Cheng, Singapore Immunology Network (SIgN)

12:10 – 12:25

Meta-analysis of Therapeutic Vaccination for CHB

Seng Gee Lim, National University of Singapore

12:25 – 12:40

Mapping of the human antibody repertoire against Hepatitis B Virus

Saket Jhajharia, National University of Singapore

12:40 – 12:55

Dysfunctional HBsAg-specific and modified global B cells in chronic hepatitis B virus infection

Loghman Salimzadeh, Duke-NUS, Singapore

12:55 – 13:15

Discussion forum led by the Moderator

13:15 – 14:00

Lunch

14:00 – 15:00

 

 

Therapeutic Strategy Forum

14:00 – 14:30

Immunological approaches for therapy to achieve functional cure

Moderator: Robert Thimme (Germany)

 

Panelists: Antonio Bertoletti (Singapore), John Connolly (Singapore), Paul McAry (Singapore), Evan Newell (Singapore)

14:30 – 15:00

Can combination therapy against virological targets achieve functional cure?
Moderator: Stephen Locarnini (Australia)
Panelists: Massimo Levrero (Italy), Zhenghong Yuan (China), Sharon Lewin (Australia)

15:00 – 15:15

Tea Break

15:15 – 16:05

 

 

 

 

Combination Therapy Symposium

Chair and Moderator: Seng Gee Lim (Singapore)

15:15 – 15:30

Summary of HBV Forum combination therapy workgroup

Bruce Given, Arrrowhead

15:30 – 15:45

Published studies of combination antiviral therapy

Robert Gish, Stanford University, USA

15:45 – 15:55

Achieving functional control of HBV and HDV infection using nucleic acid polymer-based combination therapy

Andrew Vaillant, Replicor

15:55 – 16:05

Combination treatment of a TLR7 agonist RO7020531 and a capsid assembly modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model

Lu Gao, Roche

16:05 – 16:15

Potential Combination Therapies – Summary 2018 Update

Edward Gane, University of Auckland, New Zealand

16:15 – 17:30

Combination Therapy Forum

Moderators: Sharon Lewin (Australia)  & Edward Gane (New Zealand)

 

16:15 – 17:30

Stephen Locarnini (Australia), Stephan Urban (Germany), Robert Thimme (Germany), Anuj Gaggar (Gilead Sciences), Andrew Vaillant (Replicor), Bruce Given (Arrowhead Pharmaceuticals), Cynthia Wat (Roche), Oliver Lenz (Janssen Pharmaceutica ), Uri Lopatin (Assembly), Amy Lee (Arbutus Biopharma), Nezam Afdhal (Spring Bank Pharmaceuticals)

17:30

Closing remarks from Chairman